Inherited thrombophilia and IVF failure: The impact of coagulation disorders on implantation process

American Journal of Reproductive Immunology

Volumn 68, Issue 3, 2012, Pages 189-198

  Ivanov, Petar ^a,b   Tsvyatkovska, Tsvetomira ^a   Konova, Emiliana ^c   Komsa Penkova, Regina ^b  

^a Clinical Institute for Reproductive Medicine   (Bulgaria)

^b MEDICAL UNIVERSITY PLEVEN   (Bulgaria)

^c University Hospital   (Bulgaria)

Author keywords

Assisted reproduction; Implantation failure; Inherited thrombophilic mutations

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BETA3 INTEGRIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN;

BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CELL ADHESION; CYTOTROPHOBLAST; EMBRYO DEATH; EMBRYO DEVELOPMENT; ENDOMETRIUM; ENZYME POLYMORPHISM; FERTILIZATION IN VITRO; FIBRINOLYSIS; HUMAN; HYPOFIBRINOLYSIS; NIDATION; PREGNANCY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOPHILIA; TREATMENT FAILURE;

EMBRYO IMPLANTATION; ENDOMETRIUM; EXTRACELLULAR MATRIX; FACTOR V; FEMALE; FERTILIZATION IN VITRO; HUMANS; INFERTILITY; INTEGRIN ALPHAVBETA3; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET MEMBRANE GLYCOPROTEIN IIB; PROTHROMBIN; THROMBOPHILIA; TREATMENT FAILURE; TROPHOBLASTS;

EID: 84865307504     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2012.01156.x     Document Type: Review

References (90)

1. Society for Reproductive Technology: Clinic summary report. Available at: https://www.sartcorsonline.com/rptCSR_PublicMultYear. Accessed January 9, 2008.
2. Qublan HS, Malkawi HY, Tahat YA, Areidah S, Nusair B, Khreisat BM, Al-Quraan G, Abu-Assaf A, Hadaddein MF, Abu-Jassar H: In-vitro fertilisation treatment: factors affecting its results and outcome. J Obstet Gynaecol 2005; 25:689-693.
3. Kovacs P, Matyas S, Boda K, Kaali SG: The effect of endometrial thickness on IVF/ICSI outcome. Hum Reprod 2003; 18:2337-2341.
4. Stylianou C, Critchlow D, Brison DR, Roberts SA: Embryo morphology as a predictor of IVF success: an evaluation of the proposed UK ACE grading scheme for cleavage stage embryos. Hum Fertil (Camb) 2012; 15:11-17.
5. Kawato H, Tabata T, Minoura H, Murabayashi N, Ma N, Wang DF, Sagawa N: Factor XII gene expression in endometrial stromal cells during decidualisation. Reprod Fertil Dev 2009; 21:840-847.
6. Middeldorp S: Evidence-based approach to thrombophilia testing. J Thromb Thrombolysis 2011; 31:275-278.
7. Rosendaal FR: Venous thrombosis: a multicausal disease. Lancet 1999; 353:1167-1173.
8. Munne S, Lee A, Rosenwak Z, Grifo J, Cohen: Diagnosis of major chromosome aneuploidies in human preimplantation embryos. Hum Reprod 1993; 8:2185-2191.
9. Lipe B, Ornstein DL: Deficiencies of natural anticoagulants, protein C, protein S, and antithrombin. Circulation 2011; 124:365-368.
10. Cacciapuoti F: Some considerations about the hypercoagulable states and their treatments. Blood Coagul Fibrinolysis 2011; 22:155-159.
11. Segers K, Dahlback B, Nicolaes GA: Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost 2007; 98:530-542.
12. Rees DC, Cox M, Clegg JB: World distribution of factor V Leiden. Lancet 1995; 346:1133-1134.
13. Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N: Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82:6-9.
14. Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N, Inbal A: Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 2002; 17:1633-1637.
15. Reznikoff-Etievan MF, Cayol V, Carbonne B: Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage. BJOG 2001; 108:1251-1254.
16. Younis JS, Brenner B, Ohel G, Tal J, Lanir N, Ben-Ami M: Activated protein C resistance and factor V Leiden mutation can be associated with fi rst- as well as secondtrimester recurrent pregnancy loss. Am J Reprod Immunol 2000; 43:31-35.
17. Goodman C, Jeyendran RS, Coulam CB: P53 tumor suppressor factor, plasminogen activator inhibitor, and vascular endothelial growth factor gene polymorphisms and recurrent implantation failure. Fertil Steril 2009; 92:494-498.
18. Coulam CB, Jeyendran RS, Fishel LA, Roussev R: Multiple thrombophilic gene mutations are risk factors for implantation failure. Reprod Biomed Online 2006; 12:322-327.
19. Qublan HS, Eid SS, Ababneh HA, Amarin ZO, Smadi AZ, Al-Khafaji FF, Khader YS: Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer failure. Hum Reprod 2006; 21:2694-2698.
20. Enders AC, Schlafke S, Hendrickx AG: Differentiation of the embryonic disc, amnion, and yolk sac in the rhesus monkey. Am J Anat 1986; 177:161-185.
21. Lessey BA: Assessment of endometrial receptivity. Fertil Steril 2011; 96:522-529.
22. Margadant C, Monsuur HN, Norman JC, Sonnenberg A: Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol 2011; 23:607-614.
23. Lessey BA: Embryo quality and endometrial receptivity: lessons learned from the ART experience. J Assist Reprod Genet 1998; 15:173-176.
24. Lessey BA, Damjanovich L, Coutifaris C, Castelbaum A, Albelda SM, Buck CA: Integrin adhesion molecules in the human endometrium. Correlation with the normal and abnormal menstrual cycle. J Clin Invest 1992; 90:188-195.
25. Lessey BA: Endometrial integrins and the establishment of uterine receptivity. Hum Reprod 1998; 13:247-258.
26. Sajid M, Vijayan KV, Souza S, Bray PF: PlA polymorphism of integrin_3 differentially modulates cellular migration on extracellular matrix proteins. Arterioscler Thromb Vasc Biol 2002; 22:1984-1989.
27. Liu J, Chakraborty C, Graham CH, Barbin YP, Dixon SJ, Lala PK: Noncatalytic domain of uPA stimulates human extravillous trophoblast migration by using phospholipase C, phosphatidylinositol 3-kinase and mitogen-activated protein kinase. Exp Cell Res 2003; 286:138-151.
28. Staun-Ram E, Goldman S, Gabarin D, Shalev E: Expression and importance of matrix metalloproteinase 2 and 9 (MMP-2 and -9) in human trophoblast invasion. Reprod Biol Endocrinol 2004; 2:59.
29. LaMarca HL, Ott CM, Höner Zu Bentrup K, Leblanc CL, Pierson DL, Nelson AB, Scandurro AB, Whitley GS, Nickerson CA, Morris CA: Three-dimensional growth of extravillous cytotrophoblasts promotes differentiation and invasion. Placenta 2005; 26:709-712.
30. Varanou A, Withington SL, Lakasing L, Williamson C, Burton GJ, Hemberger M: The importance of cysteine cathepsin proteases for placental development. J Mol Med (Berl) 2006; 84:305-317.
31. Blasi F, Carmeliet P: uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3:932-943.
32. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM: The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde. Thromb Haemost 1995; 74:837-841.
33. Eriksson P, Kallin B, van 'tHooft FM, Båvenholm P, Hamsten A: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92:1851-1855.
34. Tsantes AE, Nikolopoulos GK, Bagos PG, Rapti E, Mantzios G, Kapsimali V, Travlou A: Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost 2007; 97:907-913.
35. Cartwright JE, Fraser R, Leslie K, Wallace AE, James JL: Remodelling at the maternal-fetal interface: relevance to human pregnancy disorders. Reproduction 2010; 140:803-813.
36. Lockwood CJ, Krikun G, Rahman M, Caze R, Buchwalder L, Schatz F: The role of decidualization in regulating endometrial hemostasis during the menstrual cycle, gestation, and in pathological states. Semin Thromb Hemost 2007; 33:111-117.
37. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A Common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
38. Razin A, Shemer R: DNA methylation in early development. Hum Mol Genet 1995; 4:1751-1755.
39. Shi W, Haaf T: Aberrant methylation patterns at the two-cell stage as an indicator of early developmental failure. Mol Reprod Dev 2002; 63:329-334.
40. Lucock M, Daskalakis I, Briggs D, Yates Z, Levene M: Altered folate metabolism and disposition in mothers affected by a spina bifida pregnancy: influence of 677c -> t methylenetetrahydrofolate reductase and 2756a -> g methionine synthase genotypes. Mol Genet Metab 2000; 70:27-44.
41. Duthie SJ, Narayanan S, Blum S, Pirie L, Brand GM: Folate deficiency in vitro induces uracil misincorporation and DNA hypomethylation and inhibits DNA excision repair in immortalized normal human colon epithelial cells. Nutr Cancer 2000; 37:245-251.
42. Castro R, Rivera I, Ravasco P, Camilo ME, Jakobs C, Blom HJ, de Almeida IT: 5, 10-methylenetetrahydrofolate reductase (MTHFR) 677C->T and 1298A->C mutations are associated with DNA hypomethylation. J Med Gene 2004; 41:454-458.
43. Robien K, Ulrich CM: 5, 10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE minireview. Am J Epidemiol 2003; 157:571-582.
44. Nelen WL, Blom HJ, Thomas CM, Steegers EA, Boers GH, Eskes TK: Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages. J Nutr 1998; 128:1336-1341.
45. Isotalo PA, Wells GA, Donnelly JG: Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: an examination of C677T and A1298C mutations. Am J Hum Genet 2000; 67:986-990.
46. Zetterberg H, Regland B, Palmér M, Ricksten A, Palmqvist L, Rymo L, Arvanitis DA, Spandidos DA, Blennow K: Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur J Hum Genet 2002; 10:113-118.
47. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G: Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43:414-421.
48. Guenther BD, Sheppard CA, Tran P, Rozen R, Matthews RG, Ludwig ML: The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nat Struct Biol 1999; 6:359-365.
49. Szymański W, Kazdepka-Ziemińska A: Effect of homocysteine concentration in follicular fluid on a degree of oocyte maturity. Ginekol Pol 2003; 74:1392-1396.
50. Dobson AT, Davis RM, Rosen MP, Shen S, Rinaudo PF, Chan J, Cedars MI: Methylenetetrahydrofolate reductase C677T and A1298C variants do not affect ongoing pregnancy rates following IVF. Hum Reprod 2007; 22:450-456.
51. Heby O: DNA methylation and polyamines in embryonic development and cancer. Int J Dev Biol 1995; 39:737-757.
52. Nelen WLDM, Bulten J, Steegers EAP, Blom HJ, Hanselaar AGJ, Eskes TKAB: Maternal homocystine and chorionic vascularization in recurrent early pregnancy loss. Hum Reprod 2000; 15:953-960.
53. Martinelli I, Taioli E, Ragni G, Levi-Setti P, Passamonti SM, Battaglioli T, Lodigiani C, Mannucci PM: Embryo implantation after assisted reproductive procedures and maternal thrombophilia. Haematologica 2003; 88:789-793.
54. Azem F, Many A, Ben Ami I, Yovel I, Amit A, Lessing JB, Kupferminc MJ: Increased rates of thrombophilia in women with repeated IVF failures. Hum Reprod 2004; 19:368-370.
55. Ivanov P, Komsa-Penkova R, Kovacheva K, Konova E, Todorova K, Simeonova M, Ivanov I, Stoǐkov S, Popov I, Tanchev S, Bozhinova S: Risk of thrombophilia in carriers of thrombophilic genetic factors in unsuccessful assisted reproduction. Akush Ginekol (Sofiia) 2007; 46:3-8.
56. Coulam CB, Jeyendran RS, Fishel LA, Roussev RG: Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am J Reprod Immunol 2006; 55:360-368.
57. Qin X, Li J, Cui Y, Liu Z, Zhao Z, Ge J, Guan D, Hu J, Wang Y, Zhang F, Xu X, Wang X, Xu X, Huo Y: MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults. Nutr J 2012; 11:2.
58. Crider KS, Quinlivan EP, Berry RJ, Hao L, Li Z, Maneval D, Yang TP, Rasmussen SA, Yang Q, Zhu JH, Hu DJ, Bailey LB: Genomic DNA methylation changes in response to folic acid supplementation in a population-based intervention study among women of reproductive age. PLoS One 2011; 6:28144.
59. Rimm EB, Stampfer MJ: Folate and cardiovascular disease: one size does not fit all. Lancet 2011; 378:544-546.
60. Lockwood CJ, Toti P, Arcuri F, Norwitz E, Funai EF, Huang ST, Buchwalder LF, Krikun G, Schatz F: Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia. Am J Pathol 2007; 170:1398-1405.
61. Rouselle D, Jarrel J, Belbeck L, Andryjowicz E, Hibbert P, McMahon A: Thrombin as an adjuvant to reanastomosis of the fallopian tubes reduces implantations in the rabbit. Can J Surg 1988; 31:66-68.
62. Ivanov PD, Komsa-Penkova RS, Konova EI, Kovacheva KS, Simeonova MN, Popov JD: Association of inherited thrombophilia with embryonic and postembryonic recurrent pregnancy loss. Blood Coagul Fibrinolysis 2009; 20:134-140.
63. Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID: Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79:1166-1170.
64. Grandone E, Colaizzo D, Lo Bue A, Checola MG, Cittadini E, Margaglione M: Inherited thrombophilia and in vitro fertilization implantation failure. Fertil Steril 2001; 76:201-202.
65. Simur A, Ozdemir S, Acar H, Colakoǧlu MC, Görkemli H, Balci O, Nergis S: Repeated in vitro fertilization failure and its relation with thrombophilia. Gynecol Obstet Invest 2009; 67:109-112.
66. Göpel W, Ludwig M, Junge AK, Kohlmann T, Diedrich K, Möller J: Selection pressure for the factor-V-Leiden mutation and embryo implantation. Lancet 2001; 358:1238-1239.
67. Toth B, Vocke F, Rogenhofer N, Friese K, Thaler CJ, Lohse P: Paternal thrombophilic gene mutations are not associated with recurrent miscarriage. Am J Reprod Immunol 2008; 60:325-332.
68. Juul K, Tybjaerg-Hansen A, Nordestgaard BG: Factor V Leiden: relation to fertility? Lancet 2002; 359:894.
69. Bellver J, Soares SR, Alvarez C, Muñoz E, Ramírez A, Rubio C, Serra V, Remohí J, Pellicer A: The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion. Hum Reprod 2008; 23:278-284.
70. Coulam CB: Implantation failure and immunotherapy. Hum Reprod 1995; 10:1338-1340.
71. Urman B, Yakin K, Balaban B: Recurrent implantation failure in assisted reproduction: how to counsel and manage. B. Treatment options that have not been proven to benefit the couple. Reprod Biomed Online 2005; 11:371-381.
72. Lang IM, Moster KM, Schleef RR: Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism. Arterioscler Thromb Vasc Biol 1998; 18:808-815.
73. Gris JC, Ripart-Neveu S, Maugard C, Tailland ML, Brun S, Courtieu C, Biron C, Hoffet M, Hédon B, Marès P: Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 1997; 77:1096-1103.
74. Dzhandzhgava Zh G, Bitsadze VO: IVF failures: maternal thrombophilia as a possible cause. Georgian Med News 2005; 125:23-26.
75. Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK: Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999; 48:1589-1595.
76. Velazquez EM, Mendoza SG, Wang P, Glueck CJ: Metformin therapy is associated with decreased plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with polycystic ovary syndrome. Metabolism 1997; 46:454-457.
77. Lambrinoudaki I, Armeni E, Kaparos GJ, Christodoulakos GE, Sergentanis TN, Alexandrou A, Creatsa M, Kouskouni E: The frequency of early, spontaneous miscarriage associated with the leu33pro polymorphism of Glycoprotein IIIa: a pilot study. Aust N Z J Obstet Gynaecol 2010; 50:485-490.
78. Ivanov PD, Komsa-Penkova RS, Konova EI, Tsvyatkovska TM, Kovacheva KS, Simeonova MN, Tanchev SY: Polymorphism A1/A2 in the cell surface integrin subunit β3 and disturbance of implantation and placentation in women with recurrent pregnancy loss. Fertil Steril 2010; 94:2843-2845.
79. Nardo LG, Bartoloni G, Di Mercurio S, Nardo F: Expression of alpha(v)beta3 and alpha4beta1 integrins throughout the putative window of implantation in a cohort of healthy fertile women. Acta Obstet Gynecol Scand 2002; 81:753-758.
80. Arias F, Romero R, Joist H, Kraus FT: Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions of the placenta. J Matern Fetal Med 1998; 7:277-286.
81. Weckstein LN, Jacobson A, Galen D, Hampton K, Hammel J: Low-dose aspirin for oocyte donation recipients with a thin endometrium: prospective, randomized study. Fertil Steril 1997; 68:927-930.
82. Ruopp MD, Collins TC, Whitcomb BW, Schisterman EF: Evidence of absence or absence of evidence? A reanalysis of the effects of low-dose aspirin in in vitro fertilization Fertil Steril 2008; 90:71-76.
83. Lok IH, Yip SK, Cheung LP, Yin Leung PH, Haines CJ: Adjuvant low-dose aspirin therapy in poor responders undergoing in vitro fertilization: a prospective, randomized, double-blind, placebo-controlledtrial. Fertil Steril 2004; 81:556-561.
84. Lambers MJ, Mijatovic V, Hompes PG: Low dose aspirin and IVF: 'is it time for a meta-analysis'? Continued: the consequences of the choices made Hum Reprod Update 2009; 15:262-263.
85. Zhao M, Chang C, Liu Z, Chen LM, Chen Q: Treatment with low-dose aspirin increased the level LIF and integrin β3 expression in mice during the implantation window. Placenta 2010; 31:1101-1105.
86. Szczeklik A, Undas A, Sanak M, Frolow M, Wegrzyn W: Relationship between bleeding time, aspirin and the PlA1/A2 polymorphism of platelet glycoprotein IIIa. Br J Haematol 2000; 110:965-967.
87. Pamukcu B, Oflaz H, Nisanci Y: The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am Heart J 2005; 149:675-680.
88. Kay C, Jeyendran RS, Coulam CB: P53 tumour suppressor polymorphism is associated with recurrent implantation failure. Reprod Biomed Online 2006; 13:492-496.
89. Goodman C, Jeyendran RS, Coulam CB: Vascular endothelial growth factor gene polymorphisms and recurrent implantation failure. Reprod Biomed Online 2008; 16:720-727.
90. Tranquilli AL, Saccucci F, Giannubilo SR, Cecati M, Nocchi L, Lorenzi S, Emanuelli M: Unexplained fetal loss: the fetal side of thrombophilia. Fertil Steril 2010; 94:378-380.